Method and system for determining a risk of hemodynamic compromise after cardiac intervention
Inventors
Mortier, Peter Eddy J. • Debusschere, Nic • De Santis, Gianluca • DeZutter, Tim • De Beule, Matthieu Robert Anna Firmin
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11331149-B2
Publication Date
2022-05-17
Expiration Date
Abstract
A method and system for predicting a measure of hemodynamic compromise as a result of transcatheter cardiac treatment. The method includes providing a patient-specific anatomical model representing cardiac region and an implant model representing a three-dimensional representation of a cardiac implant. The method includes virtually deploying said implant model into said patient-specific anatomical model. A deformation of the patient-specific anatomical model is calculated as a result of implant model deployment A measure of hemodynamic compromise is determined from the virtually deployed implant model and the deformed patient-specific anatomical model.
Core Innovation
The disclosed invention provides a computer-based pre-operative planning framework for predicting hemodynamic compromise after transcatheter cardiac valve and interventional treatment. It addresses the need to assess hemodynamic outcomes prior to treatment for a patient-specific anatomy and a selected implant model.
The framework uses a patient-specific finite-element anatomical model together with a 3D finite-element implant/valve model. It virtually deploys the implant into the anatomical model, computes anatomical deformation, and determines a quantitative hemodynamic compromise measure for blood flow through primary and/or secondary blood flow paths.
The hemodynamic compromise measure is based on predicted obstruction and/or leakage, including features such as LVOT obstruction and obstruction and/or leakage for secondary flow paths. The prediction can evaluate temporal effects across cardiac-cycle moments and staged deployment, and optionally include leaflet displacement simulation and computational fluid dynamics and/or fluid-structure interaction.
Claims Coverage
Not explicitly described in patent.
Not explicitly described in patent.
Stated Advantages
Enables patient-specific pre-operative prediction of hemodynamic compromise after transcatheter cardiac valve and interventional treatment.
Provides quantitative assessment of hemodynamic compromise for primary and/or secondary blood flow paths using predicted obstruction and/or leakage.
Supports evaluation of temporal effects across cardiac-cycle moments and staged deployment, including optional leaflet displacement simulation.
Outputs risk information to support selecting optimal implant model(s) and deployment location(s).
Documented Applications
Pre-operative planning to predict hemodynamic compromise after transcatheter cardiac valve/interventional treatment.
Risk assessment and selection of optimal implant model(s) and deployment location(s) for transcatheter valve treatment (e.g., TAVI/TMVR/TTVR, as described).
Interested in licensing this patent?